1.52
  Price3.18%   -0.0500
(After Hours: 1.54 +0.0200 +1.32%)
Apr-22-21 08:00AM Evofem Biosciences to Report First Quarter 2021 Results and Provide Corporate Update on Thursday, May 6, 2021PR Newswire
Apr-21-21 08:00AM Evofem Biosciences to Deliver Keynote Address and Present Two Phexxi Data Sets at NCODA 2021 National Spring ForumPR Newswire
Mar-29-21 04:05AM Evofem Biosciences Announces Closing of Public Offering of Common StockPR Newswire
Mar-25-21 07:58AM The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq DebutBenzinga
Mar-24-21 10:00AM Evofem Biosciences Announces Pricing of $30 Million Public Offering of Common StockPR Newswire
04:00AM Evofem Biosciences Announces Proposed Public Offering of Common StockPR Newswire
Mar-17-21 08:00AM Evofem Biosciences' DTC Campaign "Get Phexxi" Delivers Strong Initial ImpactPR Newswire
Mar-16-21 08:00AM Evofem Biosciences Announces Publication in American Journal of Obstetrics and Gynecology of AMPREVENCE Study of EVO100 for Chlamydia and Gonorrhea PreventionPR Newswire
Mar-06-21 03:05AM What Type Of Shareholders Make Up Evofem Biosciences, Inc.'s (NASDAQ:EVFM) Share Registry?Simply Wall St.
Mar-05-21 01:00AM Why Evofem Biosciences Stock Is Falling TodayMotley Fool
10:38AM ROCE Insights For Evofem BiosciencesBenzinga
Mar-04-21 04:00AM Evofem Biosciences Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate UpdatePR Newswire
02:30AM Evofem Biosciences, Inc. to Host Earnings CallACCESSWIRE
Feb-23-21 08:00AM Evofem Biosciences to Present at H.C. Wainwright Global Life Sciences ConferencePR Newswire
Feb-18-21 08:00AM Evofem Biosciences to Report Fourth Quarter and Year-End 2020 Results and Provide Corporate Update on Thursday, March 4, 2021PR Newswire
Feb-16-21 08:00AM Evofem Biosciences Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of Phexxi®, A Non-Hormonal Birth Control Option for WomenPR Newswire
Feb-04-21 09:00AM Evofem Biosciences and NCODA Announce Collaboration to Educate Oncology Community about Phexxi®, A Non-Hormonal Birth Control Option for Women with CancerPR Newswire
Jan-12-21 09:05AM Evofem Biosciences Wins Business Intelligence Group's BIG Innovation Award 2021PR Newswire
Dec-22-20 07:00AM Evofem Biosciences to Participate in Medicaid National Drug Rebate Program for Phexxi® Effective January 1, 2021PR Newswire
Dec-21-20 09:00AM Evofem Biosciences to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual ConferencePR Newswire
Dec-17-20 07:00AM Evofem Biosciences Provides Update on Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and GonorrheaPR Newswire
Dec-12-20 03:12AM Is EVFM A Good Stock To Buy Now?Insider Monkey
Dec-11-20 08:00AM Evofem Biosciences Announces Orange Book Listing of Two U.S. Patents for Phexxi®PR Newswire
Dec-03-20 07:00AM The U.S. Department of Veterans Affairs Awards Contract to Evofem Biosciences for Phexxi®PR Newswire
Nov-20-20 08:30AM Evofem Biosciences to Participate in Piper Sandler 32nd Annual Virtual Healthcare ConferencePR Newswire
Nov-12-20 08:30AM Evofem Biosciences to Present at Stifel Virtual Healthcare ConferencePR Newswire
Nov-09-20 11:00AM Evofem Biosciences, Inc. (EVFM) Q3 2020 Earnings Call TranscriptMotley Fool
04:01AM Evofem Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate UpdatePR Newswire
Nov-09-20 03:15AM Evofem Biosciences, Inc. to Host Earnings CallACCESSWIRE
Oct-27-20 08:00AM Evofem Biosciences to Report Third Quarter 2020 Results and Provide Corporate Update on Monday, November 9, 2020PR Newswire
Oct-26-20 09:00AM Evofem Biosciences to Participate in Virtual Investor KOL RoundtablePR Newswire
Oct-20-20 08:00AM Evofem Biosciences Announces First Patient Enrolled in Pivotal Phase 3 Trial of EVO100 for Prevention of Chlamydia and GonorrheaPR Newswire
Oct-08-20 10:15AM Unusual Options Activity Insight: Evofem BiosciencesBenzinga
Oct-07-20 08:00AM Evofem Biosciences Announces Presentations on Phexxi and EVO100 at Key Medical Society MeetingsPR Newswire
Sep-16-20 12:13PM Evofem Biosciences Announces Updated Date and Time for Fireside Chat at Cantor Global Virtual Healthcare ConferencePR Newswire
Sep-14-20 09:42AM Is the Options Market Predicting a Spike in Evofem Biosciences (EVFM) Stock?Zacks
09:00AM Evofem Biosciences to Present Data at the 2020 STD Prevention Virtual Conference from Phase 2b Trial of EVO100 for Prevention of Chlamydia and Gonorrhea in WomenPR Newswire
Sep-11-20 12:02PM Why Evofem Biosciences Stock Is Plunging TodayMotley Fool
10:27AM Return On Capital Employed Overview: Evofem BiosciencesBenzinga
Sep-07-20 11:57AM What Is The Ownership Structure Like For Evofem Biosciences, Inc. (NASDAQ:EVFM)?Simply Wall St.
Aug-31-20 09:00AM Evofem Biosciences to Participate in Four Upcoming Investor ConferencesPR Newswire
Aug-21-20 06:00AM Evofem Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
Aug-20-20 09:51AM Benzinga's Top Upgrades, Downgrades For August 20, 2020Benzinga
Aug-11-20 08:53AM Do Options Traders Know Something About Evofem Biosciences (EVFM) Stock We Don't?Zacks
Aug-04-20 09:31AM Evofem Biosciences, Inc. (EVFM) Q2 2020 Earnings Call TranscriptMotley Fool
08:00AM Evofem Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate UpdatePR Newswire
Aug-03-20 08:30AM Evofem Biosciences' CEO Saundra Pelletier Named to PharmaVOICE100 - The Most Inspiring People in Life SciencesPR Newswire
Jul-23-20 08:30AM Evofem Biosciences to Report Second Quarter 2020 Results and Provide Corporate Update on Tuesday, August 4, 2020PR Newswire
Jul-21-20 03:55AM Edited Transcript of EVFM.OQ earnings conference call or presentation 6-Aug-19 3:00pm GMTThomson Reuters StreetEvents
03:55AM Edited Transcript of EVFM.OQ earnings conference call or presentation 7-Nov-19 4:00pm GMTThomson Reuters StreetEvents
Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes women's sexual and reproductive health products. Its lead product candidate is Amphora that is in Phase 3 trial for contraception; and in Phase 2b/3 clinical trial for prevention of chlamydia and gonorrhea in women. The company is also developing vaginal gel product candidate for the treatment of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
Cap:    |  Volume (24h):